Adel Kardosh, Ph.D.
Affiliations: | 2007 | Molecular Microbiology & Immunology: Doctor of Philosophy | University of Southern California, Los Angeles, CA, United States |
Area:
Molecular Biology, PharmacyGoogle:
"Adel Kardosh"Parents
Sign in to add mentorAxel H. Schonthal | grad student | 2007 | USC | |
(Identification of the targets required for the anti-tumor effect of celecoxib and its non-COX-2 inhibitory derivative.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Sallets A, Robinson S, Kardosh A, et al. (2018) Enhancing immunotherapy of STING agonist for lymphoma in preclinical models. Blood Advances. 2: 2230-2241 |
Czerwinski DK, Long SR, Khodadoust M, et al. (2016) Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cyotmetry in Previously Untreated Patients Blood. 128: 2947-2947 |
Ladner RD, Kahn M, Yang D, et al. (2013) Risk of tumor-related death in stage I-III colon cance based on gender and tumor location. Journal of Clinical Oncology. 31 |
Schultheis AM, Volz NB, Zhang W, et al. (2013) Use of genetic variants in immune response genes to predict clinical outcome in mCRC patients treated with cetuximab-based therapy. Journal of Clinical Oncology. 31: 3567-3567 |
Volz NB, Zhang W, Yang D, et al. (2013) Use of genetic variants in pericyte-driven tumor vessel maturation genes to predict treatment efficacy in mCRC patients treated with FOLFIRI/bevacizumab. Journal of Clinical Oncology. 31: 3566-3566 |
Virrey JJ, Liu Z, Cho HY, et al. (2010) Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. Molecular Cancer Therapeutics. 9: 631-41 |
Golden EB, Lam PY, Kardosh A, et al. (2009) Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 113: 5927-37 |
Chuang HC, Kardosh A, Gaffney KJ, et al. (2008) COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro Molecular Cancer. 7 |
Kardosh A, Golden EB, Pyrko P, et al. (2008) Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Research. 68: 843-51 |
Pyrko P, Kardosh A, Schönthal AH. (2008) Celecoxib transiently inhibits cellular protein synthesis. Biochemical Pharmacology. 75: 395-404 |